SCHEMBL9204579

SCHEMBL9204579

CC(C)Nc1ncnc2nc[nH]c12

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.66
HSD17B10 Q99714 4/20 0.66
SMN1; SMN2 Q16637 3/20 0.66
HTT P42858 6/20 0.57
CYP1A2 P05177 2/20 0.55
PAK1 Q13153 1/20 0.55
HIF1A Q16665 1/20 0.55
PKM P14618 1/20 0.54
CYP3A4 P08684 1/20 0.53
CDK2 P24941 1/20 0.51
RAB9A P51151 2/20 0.50
NPC1 O15118 1/20 0.50
MKNK1 Q9BUB5 1/20 0.50
PRMT1 Q99873 1/20 0.50
PIK3CG P48736 1/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
GFER P55789 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3730455 0.86 LMNA (0.62) LMNAHSD17B10SMN1; SMN2HTTCYP1A2
SCHEMBL21914 0.79 HTT (0.62) LMNAHSD17B10SMN1; SMN2HTTCYP1A2
SCHEMBL29380490 0.79 HTT (0.62) LMNAHSD17B10SMN1; SMN2HTTCYP1A2
SCHEMBL16145699 0.78 HTT (0.65) LMNAHSD17B10SMN1; SMN2HTTCYP1A2
SCHEMBL6243538 0.78 HTT (0.60) LMNAHSD17B10SMN1; SMN2HTTCYP1A2
SCHEMBL10918760 0.78 HTT (0.60) LMNAHSD17B10SMN1; SMN2HTTCYP1A2
SCHEMBL25176526 0.78 SMN1; SMN2 (0.54) LMNAHSD17B10SMN1; SMN2HTTCYP1A2
SCHEMBL11591794 0.77 HTT (0.59) LMNAHSD17B10SMN1; SMN2HTTCYP1A2
SCHEMBL31095854 0.77 CYP1A2 (0.57) LMNAHSD17B10SMN1; SMN2HTTCYP1A2
SCHEMBL405823 0.76 HTT (0.58) LMNAHSD17B10SMN1; SMN2HTTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022155418-A9 MODIFIED OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC. (US) 2023-03-09 WO disclosed
WO-2023028350-A1 THERAPEUTIC COMPOSITIONS AND RELATED METHODS BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) 2023-03-02 WO disclosed
EP-0286425-B1 Therapeutic nucleosides WELLCOME FOUND (GB) 1995-01-11 EP disclosed
US-5185437-A 6-substituted 2',3'-dideoxypurine nucleosides; treatment for human immunodeficiency virus and heptatis b virus BURROUGHS WELLCOME CO. (US) 1993-02-09 US disclosed
US-5068320-A 2-amino-6-(cyclopropylamino)purine-9-β-D-2',3'-dideoxyribofuranoside and its pharmaceutically acceptable salts BURROUGHS WELLCOME CO. (US) 1991-11-26 US disclosed
US-4849423-A Purine derivatives, medicaments containing them and methods of treating cardiac insufficiencies and irregularities with them. SANDOZ LTD. (CH) 1989-07-18 US disclosed
EP-0286425-A2 Therapeutic nucleosides THE WELLCOME FOUNDATION LIMITED (GB) 1988-10-12 EP disclosed